Page 404 - Read Online

Page 16 of 16 Pearce et al. Neuroimmunol Neuroinflammation 2018;5:47 I http://dx.doi.org/10.20517/2347-8659.2018.46

71. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, et al. Dendritic cells process synthetic long peptides better than whole
protein, improving antigen presentation and T-cell activation. Eur J Immunol 2013;43:2554-65.
72. Vigneron N. Human tumor antigens and cancer immunotherapy. Biomed Res Int 2015;2015:948501.
73. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. Immunologic escape after prolonged progression-free
survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin
Oncol 2010;28:4722-9.
74. Weller M, Butowski N, Tran DD, Recht LD, Lim M, et al. Rindopepimut with temozolomide for patients with newly diagnosed,
EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017;18:1373-85.
75. Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, et al. ReACT: overall survival from a randomized phase II study of
rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 2015;33:2009.
76. Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in
patients with recurrent malignant glioma. Cancer Immunol Immunother 2016;65:1339-52.
77. Dutoit V, Migliorini D, Patrikidou A, Mayer-Mokler A, Hilf N, et al. IMA950 multipeptide vaccine adjuvanted with poly-ICLC in
combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients. Ann Oncol 2017;28:xi3-5.
78. Wick W, Dietrich PY, Kuttruff S, Hilf N, Frenzel K, et al. GAPVAC-101: First-in-human trial of a highly personalized peptide
vaccination approach for patients with newly diagnosed glioblastoma. J Clin Oncol 2018;36:2000.
79. Yaddanapudi K, Mitchell RA, Putty K, Willer S, Sharma RK, et al. Vaccination with embryonic stem cells protects against lung cancer:
is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One 2012;7:e42289.
80. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med
2013;19:998-1004.
81. Inoue H, Watanabe A, Sakamoto C, Narusawa M, Hiramoto T, et al. Vaccination with irradiated induced pluripotent stem cells
genetically engineered to produce GM-CSF confers potent t-cells-mediated antitumor immunity. Blood 2013;122:4492.
82. Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in
vivo. Cell Stem Cell 2018;22:501-13.
83. Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol Med 2001;7:659-67.
84. Polyzoidis S, Ashkan K. DCVax®-L--Developed by Northwest Biotherapeutics. Hum Vaccin Immunother 2014;10:3139-45.
85. Lasky JL 3rd, Panosyan EH, Plant A, Davidson T, Yong WH, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for
pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013;33:2047-56.
86. Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor
cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer 2014;2:4.
87. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for
patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013;62:125-35.
88. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, et al. Monocyte enrichment from leukapharesis products for the generation of
DCs by plastic adherence, or by positive or negative selection. Cytotherapy 2003;5:391-8.
89. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, et al. First results on survival from a large phase 3 clinical trial of an
autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 2018;16:142.
90. Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, et al. A phase II trial of autologous dendritic cell vaccination and
radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med 2017;15:104.
91. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, et al. Integration of autologous dendritic cell-based immunotherapy in the
standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol
Immunother 2012;61:2033-44.
92. Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, et al. Survival gain in glioblastoma patients treated with dendritic cell
immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.
OncoImmunology 2018;7:e1412901.
93. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, et al. Immune response in patients with newly diagnosed glioblastoma multiforme
treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011;34:382-9.
94. Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, et al. Long-term survival in glioblastoma with Cytomegalovirus pp65-
targeted vaccination. Clin Cancer Res 2017;23:1898-1909.
95. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, et al. Therapeutic vaccination against autologous cancer stem cells
with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013;62:1499-509.